---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-027168"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:14:54.557473+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M

## Summary
- Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.
- Operating income fell to $30K from $585K in the year-ago quarter.
- Net loss of $35K ($0.00 EPS) vs net income of $516K ($0.02) in Q1 FY2022.
- Two largest Contract Manufacturing customers were 85% of revenue (down from 91%).
- Co-CEOs cite pandemic overstocking by customers as key headwind.

## SEC filing metadata
- accession: 0001437749-22-027168
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/0001437749-22-027168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/inbp20221110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-027168
- JSON: https://secwatch.observer/filing/0001437749-22-027168.json
- Plain text: https://secwatch.observer/filing/0001437749-22-027168.txt

## Key facts
- Earnings Releases
  INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.
  - Period: the quarter ended September 30, 2022
  - Revenue: $12.3 million
  - Net income: net loss of approximately $35,000 or $0.00 per share of common stock
  - EPS: $0.00 per share of common stock
  - Result: reported results
  source text: Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 HILLSIDE, NEW JERSEY (November 10, 2022) - Integrated BioPharma, Inc. (OTCQX: INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774922027168/0001437749-22-027168-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.